| Quartiles of serum SepP concentration (mg/L) | Continuous (per 1 mg/L) |
<2.58 | 2.58-2.90 | 2.90-3.24 | ≥3.24 |
Cases/controls (n) | 61/121 | 53/124 | 74/119 | 59/127 | |
Crude OR* (95% CI) | 1.00 | 0.84 (0.54, 1.33) | 1.22 (0.79, 1.88) | 0.91 (0.57, 1.44) | 0.85 (0.62, 1.17) |
Adjusted OR† (95% CI) | 1.00 | 0.83 (0.52, 1.33) | 1.07 (0.68, 1.88) | 0.83 (0.51, 1.33) | 0.77 (0.55, 1.07) |
Excluding cases diagnosed during 1st year of follow-up (and matched controls) |
Cases/controls (n) | 58/116 | 50/116 | 68/115 | 58/118 | |
Adjusted OR† (95% CI) | 1.00 | 0.85 (0.53, 1.36) | 1.00 (0.63, 1.59) | 0.88 (0.54, 1.43) | 0.79 (0.56, 1.11) |
High-grade prostate cancer |
Cases/controls (n) | 25/49 | 18/34 | 28/41 | 20/58 | |
Adjusted OR† (95% CI) | 1.00 | 0.98 (0.46, 2.06) | 1.13 (0.55, 2.29) | 0.57 (0.27, 1.22) | 0.62 (0.37, 1.05) |
Low-grade prostate cancer |
Cases/controls (n) | 33/66 | 27/71 | 37/64 | 33/56 | |
Adjusted OR† (95% CI) | 1.00 | 0.75 (0.39, 1.44) | 1.08 (0.57, 2.04) | 1.07 (0.55, 2.11) | 0.89 (0.56, 1.42) |